-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, China Resources Shuanghe (600062.SH) issued an announcement. Recently, Beijing Shuanghe Runchuang Technology Co., Ltd., a wholly-owned subsidiary of the company, received the DC7001A capsule “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. This drug is intended to treat systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).

Zhitongcaijing·08/12/2026 09:01:10
Listen to the news
Zhitong Finance App News, China Resources Shuanghe (600062.SH) issued an announcement. Recently, Beijing Shuanghe Runchuang Technology Co., Ltd., a wholly-owned subsidiary of the company, received the DC7001A capsule “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. This drug is intended to treat systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).